{"hands_on_practices": [{"introduction": "To truly grasp the concept of genome instability, it's essential to move from qualitative descriptions to quantitative predictions. This first exercise guides you through building a probabilistic model from the ground up, simulating a common mechanism of instability known as microsatellite instability (MSI). By modeling DNA polymerase slippage and the efficiency of the Mismatch Repair (MMR) system, you will derive an expression for the probability that a repetitive DNA sequence acquires a mutation, a process fundamental to the development of certain cancers [@problem_id:5025739]. This practice sharpens your ability to translate molecular events into a mathematical framework.", "problem": "Microsatellites, defined as short tandem repeats in deoxyribonucleic acid (DNA), are prone to strand misalignment during replication, leading to insertion–deletion loop formation when the nascent strand or template strand transiently slips. Strand misalignment at repeats can create a looped-out segment on one strand, which, if left uncorrected, becomes a fixed insertion or deletion in the daughter DNA after ligation. The mismatch repair (MMR) pathway scans for these indel loops and repairs them by excising the error-containing segment and resynthesizing the correct sequence, thereby restoring repeat count. Consider a single microsatellite locus of $R$ identical mononucleotide repeats. In each replication cycle, each repeat independently experiences polymerase slippage that produces a single-repeat indel loop with probability $s$. Each indel loop is recognized and corrected by mismatch repair (MMR) with efficiency $c$, meaning the loop is corrected before ligation with probability $c$ and remains as a fixed indel with probability $1-c$. Assume:\n- The direction of slippage (insertion versus deletion) is irrelevant to the calculation because we only ask whether any persistent indel occurs.\n- Slippage events are rare so they can be treated as independent Bernoulli trials across repeats and across cycles.\n- Each slippage event produces a single-repeat loop, and multiple loops in the same cycle at this locus are negligible under the given $s$.\nStarting from the basic definitions of DNA replication fidelity, strand misalignment at repeats, and probabilistic modeling of rare independent events, derive from first principles an expression for the probability that, after $N$ consecutive replication cycles, this locus has experienced at least one persistent indel (i.e., an indel that escaped repair and became fixed). Then evaluate this probability for $R=25$, $s=2.0 \\times 10^{-4}$ per repeat per cycle, $c=0.96$, and $N=40$. Express the final probability as a decimal and round your answer to four significant figures.", "solution": "The problem asks for the probability of at least one persistent indel after $N$ replication cycles. This is best calculated as $1$ minus the probability of the complementary event: zero persistent indels.\n\n1.  **Probability of a Persistent Indel in One Trial:**\n    A single \"trial\" can be considered a single repeat unit undergoing one replication cycle. For a persistent indel to occur at this single repeat, two independent events must happen in sequence:\n    *   A polymerase slippage event creates an indel loop. The probability of this is $s$.\n    *   The Mismatch Repair (MMR) system fails to correct this loop. The probability of failure is $(1-c)$.\n    The probability of a persistent indel at a single repeat in one cycle is the product of these probabilities: $p_{indel} = s \\times (1-c)$.\n\n2.  **Probability of No Persistent Indel in One Cycle:**\n    The probability that a single repeat does *not* give rise to a persistent indel in one cycle is $1 - p_{indel} = 1 - s(1-c)$.\n    Since there are $R$ repeats at the locus and slippage events are independent, the probability that *none* of the $R$ repeats form a persistent indel in one cycle is:\n    $$P(\\text{no persistent indel in 1 cycle}) = (1 - s(1-c))^R$$\n\n3.  **Probability of No Persistent Indel in N Cycles:**\n    The replication cycles are also independent. Therefore, the probability that the locus experiences no persistent indels over $N$ cycles is the probability of this outcome in one cycle, raised to the power of $N$:\n    $$P(\\text{no persistent indels in N cycles}) = \\left( (1 - s(1-c))^R \\right)^N = (1 - s(1-c))^{RN}$$\n\n4.  **Probability of at Least One Persistent Indel:**\n    The final probability is the complement of the event calculated in step 3:\n    $$P_{total} = 1 - P(\\text{no persistent indels in N cycles}) = 1 - (1 - s(1-c))^{RN}$$\n\n5.  **Numerical Evaluation:**\n    We are given the following values:\n    *   $R = 25$ repeats\n    *   $s = 2.0 \\times 10^{-4}$ per repeat per cycle\n    *   $c = 0.96$\n    *   $N = 40$ cycles\n\n    First, calculate the probability of a single persistent indel event, $p_{indel}$:\n    $$p_{indel} = s(1-c) = (2.0 \\times 10^{-4})(1 - 0.96) = (2.0 \\times 10^{-4})(0.04) = 8.0 \\times 10^{-6}$$\n\n    Next, calculate the total number of effective trials:\n    $$RN = 25 \\times 40 = 1000$$\n\n    Now, substitute these values into the derived expression:\n    $$P_{total} = 1 - (1 - 8.0 \\times 10^{-6})^{1000}$$\n    $$P_{total} = 1 - (0.999992)^{1000}$$\n\n    Calculating the value of the term in parentheses:\n    $$(0.999992)^{1000} \\approx 0.992031859$$\n\n    Finally, calculate $P_{total}$:\n    $$P_{total} \\approx 1 - 0.992031859 = 0.007968141$$\n\n    Rounding to four significant figures gives $0.007968$.", "answer": "$$\\boxed{0.007968}$$", "id": "5025739"}, {"introduction": "The cell's response to DNA damage is a story of conflict and choice, particularly when it must decide between the quick-and-dirty Non-Homologous End Joining (NHEJ) pathway and the high-fidelity Homologous Recombination (HR) pathway. This decision is governed by an intricate molecular ballet, with proteins like BRCA1 and 53BP1 acting as key antagonists. This thought experiment places you at the center of this conflict, challenging you to reason through the consequences of disrupting this balance in a cancer cell [@problem_id:5025677]. Predicting the outcome for DNA repair and, crucially, for the effectiveness of targeted therapies like PARP inhibitors, is a core skill in modern cancer genetics.", "problem": "A tumor cell line derived from a basal-like breast carcinoma harbors a truncating mutation in Breast Cancer gene 1 (*BRCA1*) that abrogates its interaction with partner and localizer of BRCA2 (*PALB2*), resulting in a canonical homologous recombination (HR) defect. Investigators introduce a frameshift knockout of tumor protein p53-binding protein 1 (*53BP1*) using clustered regularly interspaced short palindromic repeats (CRISPR), and then measure DNA end resection by replication protein A (RPA) foci and HR proficiency by RAD51 foci after ionizing radiation. They also perform clonogenic survival assays with a poly-ADP-ribose polymerase (PARP) inhibitor and with a platinum agent.\n\nUse the following fundamental base:\n- Double-strand break (DSB) repair pathway choice is governed by the extent of $5' \\to 3'$ end resection: limited resection favors non-homologous end joining (NHEJ), while extensive resection generates single-stranded DNA (ssDNA) that is first coated by RPA and then replaced by RAD51 to initiate HR in S/G2.\n- *53BP1* promotes NHEJ by protecting DNA ends and restricting resection, in part via recruitment of effectors that block nucleases at chromatin surrounding DSBs; *BRCA1* antagonizes this end protection to facilitate resection and HR when a sister chromatid is available.\n- Synthetic lethality arises when HR-deficient cells (e.g., *BRCA1*-deficient) are treated with PARP inhibitors, because replication-associated lesions are converted to DSBs that cannot be faithfully repaired without HR.\n\nWhich option best explains how *53BP1* and *BRCA1* antagonism regulates pathway choice and predicts the consequences of *53BP1* loss in this *BRCA1*-deficient background for end resection and therapy response?\n\nA. Loss of *53BP1* removes a barrier to end resection, allowing nucleases to generate ssDNA despite *BRCA1* deficiency; RPA and RAD51 foci increase in S/G2, NHEJ usage declines, HR is partially restored, sensitivity to PARP inhibition decreases, and sensitivity to platinum decreases.\n\nB. Loss of *53BP1* further impairs end resection because *BRCA1* is upstream of nucleases; RPA and RAD51 foci decrease, NHEJ increases, sensitivity to PARP inhibition increases, and sensitivity to platinum increases.\n\nC. Loss of *53BP1* increases end resection but cannot influence RAD51 loading; RPA foci increase while RAD51 foci are unchanged, microhomology-mediated end joining (MMEJ) becomes dominant, sensitivity to PARP inhibition increases, and sensitivity to platinum decreases.\n\nD. Loss of *53BP1* does not affect pathway choice when *BRCA1* is absent; end resection, RPA and RAD51 foci, and responses to PARP inhibition and platinum remain unchanged because the defect is fixed upstream.", "solution": "This problem requires reasoning through the antagonistic relationship between *BRCA1* and *53BP1* in DNA double-strand break (DSB) repair and predicting the consequences of their double loss.\n\n1.  **Initial State: *BRCA1*-Deficient Cell**\n    *   The problem states the cell is *BRCA1*-deficient, leading to a homologous recombination (HR) defect.\n    *   According to the provided principles, *BRCA1* promotes end resection, which is required for HR. *53BP1* opposes this by protecting DNA ends and promoting non-homologous end joining (NHEJ).\n    *   In a *BRCA1*-deficient cell, the pro-resection function of *BRCA1* is absent. Therefore, the anti-resection function of *53BP1* is unopposed.\n    *   This leads to limited end resection, commitment to the NHEJ pathway, and a functional defect in HR.\n    *   As a result, these cells are highly sensitive to therapies that rely on a functional HR pathway for repair, such as PARP inhibitors (which create DSBs from single-strand breaks) and platinum agents (which create interstrand crosslinks repaired by HR).\n\n2.  **Perturbation: Loss of *53BP1***\n    *   Investigators then knock out *53BP1* in this *BRCA1*-deficient background. The cell now lacks both proteins.\n    *   The primary inhibitor of end resection, *53BP1*, is now gone.\n    *   Even though the primary promoter of resection, *BRCA1*, is also absent, the removal of the *53BP1* block is sufficient to allow DNA nucleases (like CtIP and EXO1) to access the DNA ends and initiate resection.\n\n3.  **Predicted Consequences:**\n    *   **End Resection:** With the *53BP1* block removed, **end resection is restored**. This will lead to the generation of single-stranded DNA (ssDNA) overhangs, which are coated by RPA. Therefore, **RPA foci will increase**.\n    *   **HR Proficiency:** The ssDNA-RPA filament is the substrate for RAD51 loading to initiate HR. Although the *BRCA1*-dependent pathway of RAD51 loading is impaired, the availability of resected ends is the rate-limiting step. Restoring resection allows for partial, *BRCA1*-independent RAD51 loading. Thus, **RAD51 foci will increase**, and **HR is partially restored**. Consequently, reliance on NHEJ will decline.\n    *   **Therapeutic Response:** The cell's sensitivity to PARP inhibitors and platinum is due to its inability to repair DSBs via HR. By partially restoring the HR pathway, the loss of *53BP1* provides the cancer cell with a mechanism to survive these treatments. Therefore, the cell becomes more resistant. **Sensitivity to both PARP inhibition and platinum agents decreases.**\n\n4.  **Evaluation of Options:**\n    *   **A:** This option correctly states that loss of *53BP1* removes the block on resection, leading to increased RPA and RAD51 foci, partial HR restoration, and decreased sensitivity (i.e., increased resistance) to both PARP inhibitors and platinum. This perfectly matches the reasoning.\n    *   **B:** This option incorrectly claims that loss of *53BP1* *further impairs* resection. This inverts the known function of *53BP1*.\n    *   **C:** This option correctly identifies increased resection (RPA foci) but incorrectly claims RAD51 loading is unaffected. It also incorrectly predicts that sensitivity to PARP inhibition *increases*, which contradicts the known mechanism of resistance.\n    *   **D:** This option incorrectly claims that loss of *53BP1* has no effect. It fails to account for the dynamic, antagonistic balance between the two proteins.\n\nTherefore, option A provides the best explanation of the biological outcome.", "answer": "$$\\boxed{A}$$", "id": "5025677"}, {"introduction": "In the era of genomic medicine, a patient's entire genome can be sequenced to guide diagnosis and treatment. The patterns of mutations found within a tumor's DNA, known as mutational signatures, serve as historical records of the DNA repair processes that have failed. This advanced practice simulates the real-world task of a computational geneticist: to build a diagnostic classifier from genomic data [@problem_id:5025740]. You will implement a pipeline that uses mutational patterns to infer Mismatch Repair (MMR) status, a critical biomarker in oncology, providing a hands-on introduction to the powerful intersection of genomics, statistics, and clinical decision-making.", "problem": "Construct a program that, given simplified whole-exome derived mutation spectra and insertion-deletion profiles, infers mismatch repair deficiency and validates predictions against immunohistochemistry. Begin from the following fundamental base: (i) the definition of a mutational signature as a probability distribution over substitution categories, (ii) the vector-space notion of similarity quantified via the cosine of the angle between vectors, and (iii) the Bayesian decision rule under class-conditional multivariate normality with equal covariance leading to a linear discriminant in feature space. Explicitly define and use the Single Nucleotide Variant (SNV) spectrum and the microsatellite-associated insertion-deletion fraction as independent features, and treat absent features by principled marginalization rather than imputation.\n\nYour program must implement the following pipeline.\n\n- Feature extraction from SNVs:\n  - Represent each sample’s SNV spectrum as counts over the six aggregated substitution classes $[\\mathrm{C>A},\\mathrm{C>G},\\mathrm{C>T},\\mathrm{T>A},\\mathrm{T>C},\\mathrm{T>G}]$. Let the count vector be $x \\in \\mathbb{R}^6_{\\ge 0}$ with components $x_i$.\n  - Define the normalized spectrum $p \\in \\mathbb{R}^6$ by $p_i = x_i / \\sum_{j=1}^{6} x_j$ when $\\sum_{j=1}^{6} x_j > 0$. If $\\sum_{j=1}^{6} x_j = 0$, the SNV-derived feature is considered absent for that sample.\n  - Use the provided simplified reference for Mutational Signature Single Base Substitution $6$ (SBS6) as $s = (0.08, 0.06, 0.46, 0.04, 0.30, 0.06)$. Quantify similarity between $p$ and $s$ by the cosine similarity defined via the Euclidean inner product and norms: $\\cos(\\theta) = \\dfrac{\\langle p, s \\rangle}{\\|p\\|_2 \\, \\|s\\|_2}$ when $p$ is defined. If the SNV feature is absent, do not invent a value; mark it as absent.\n\n- Feature extraction from insertion-deletions (indels):\n  - For each sample, let the total indels be $I_{\\text{tot}}$ and the microsatellite-context indels be $I_{\\text{msi}}$. Define the microsatellite indel fraction $r = I_{\\text{msi}} / I_{\\text{tot}}$ when $I_{\\text{tot}} > 0$. If $I_{\\text{tot}} = 0$, the indel-derived feature is considered absent and must be marginalized.\n\n- Classification model:\n  - Map each sample to the feature vector $X = (\\cos(\\theta), r)$ in $\\mathbb{R}^2$, with one or both coordinates possibly absent.\n  - Assume two classes: mismatch repair deficient (MMRd, positive) and mismatch repair proficient (MMRp, negative). Using a labeled training set, estimate class means $\\mu_+ \\in \\mathbb{R}^2$ and $\\mu_- \\in \\mathbb{R}^2$ and the pooled covariance matrix $\\Sigma \\in \\mathbb{R}^{2 \\times 2}$ under the assumption of equal class covariances.\n  - Derive from the Bayesian decision rule under multivariate normality with equal covariance that the log-posterior difference is linear in $X$: the discriminant for class $k \\in \\{+,-\\}$ has the form $g_k(X) = X^\\top \\Sigma^{-1} \\mu_k - \\tfrac{1}{2}\\mu_k^\\top \\Sigma^{-1} \\mu_k + \\ln \\pi_k$, where $\\pi_k$ are class priors. With equal priors and available features, classify as MMRd if $g_+(X) \\ge g_-(X)$, otherwise MMRp. If one feature is absent, reduce to the corresponding one-dimensional subspace by deleting the missing coordinate in $X$, the respective coordinates in $\\mu_k$, and the corresponding rows and columns of $\\Sigma$, then apply the same discriminant logic in the reduced dimension. No feature may be imputed by arbitrary constants.\n\n- Validation:\n  - Compare predictions to immunohistochemistry (IHC) labels provided for the test set. Compute sensitivity (true positive rate), specificity (true negative rate), the F1 score for the positive class, and balanced accuracy (mean of sensitivity and specificity). All metrics must be reported as decimals rounded to three decimal places.\n\nTraining data to estimate $\\mu_+$, $\\mu_-$, and $\\Sigma$:\n- SBS6 reference $s = (0.08, 0.06, 0.46, 0.04, 0.30, 0.06)$.\n- Each training sample provides: SNV counts $(x_1,\\dots,x_6)$, indel totals $I_{\\text{tot}}$, microsatellite indels $I_{\\text{msi}}$, and IHC class ($1$ for MMRd, $0$ for MMRp).\n  1. Sample $1$: $x=(8,6,60,4,35,7)$, $I_{\\text{tot}}=40$, $I_{\\text{msi}}=30$, IHC $=1$.\n  2. Sample $2$: $x=(5,7,50,3,28,7)$, $I_{\\text{tot}}=30$, $I_{\\text{msi}}=21$, IHC $=1$.\n  3. Sample $3$: $x=(3,4,55,2,25,6)$, $I_{\\text{tot}}=25$, $I_{\\text{msi}}=17$, IHC $=1$.\n  4. Sample $4$: $x=(15,20,20,18,22,15)$, $I_{\\text{tot}}=25$, $I_{\\text{msi}}=5$, IHC $=0$.\n  5. Sample $5$: $x=(12,18,25,20,18,17)$, $I_{\\text{tot}}=20$, $I_{\\text{msi}}=5$, IHC $=0$.\n  6. Sample $6$: $x=(20,15,18,22,17,18)$, $I_{\\text{tot}}=26$, $I_{\\text{msi}}=4$, IHC $=0$.\n\nTest suite to validate predictions and metrics coverage:\n- Eight evaluation samples with varied properties (typical cases, contradictory features, and edge conditions such as zero SNVs or zero indels). Each provides SNV counts $(x_1,\\dots,x_6)$, $I_{\\text{tot}}$, $I_{\\text{msi}}$, and IHC label.\n  1. Test $1$: $x=(6,6,62,5,34,7)$, $I_{\\text{tot}}=36$, $I_{\\text{msi}}=26$, IHC $=1$.\n  2. Test $2$: $x=(18,16,20,19,18,17)$, $I_{\\text{tot}}=28$, $I_{\\text{msi}}=5$, IHC $=0$.\n  3. Test $3$: $x=(0,0,0,0,0,0)$, $I_{\\text{tot}}=10$, $I_{\\text{msi}}=8$, IHC $=1$.\n  4. Test $4$: $x=(22,18,15,20,17,18)$, $I_{\\text{tot}}=0$, $I_{\\text{msi}}=0$, IHC $=0$.\n  5. Test $5$: $x=(14,20,22,18,16,20)$, $I_{\\text{tot}}=40$, $I_{\\text{msi}}=28$, IHC $=1$.\n  6. Test $6$: $x=(5,5,55,3,30,7)$, $I_{\\text{tot}}=20$, $I_{\\text{msi}}=2$, IHC $=0$.\n  7. Test $7$: $x=(16,18,19,20,16,19)$, $I_{\\text{tot}}=22$, $I_{\\text{msi}}=4$, IHC $=0$.\n  8. Test $8$: $x=(1,1,3,0,2,1)$, $I_{\\text{tot}}=1$, $I_{\\text{msi}}=1$, IHC $=1$.\n\nYour program should produce a single line of output containing the results as a comma-separated list enclosed in square brackets, where the first element is the list of Boolean predictions for the eight test cases in order and the second element is the list of four metrics $[\\text{sensitivity},\\text{specificity},\\text{F1},\\text{balanced\\_accuracy}]$, each rounded to three decimal places. For example, the output must look like $[[\\text{True},\\dots,\\text{False}],[0.123,0.456,0.789,0.321]]$ with exactly eight Booleans and four decimals. No physical units are involved; all metrics must be decimals, not percentages.", "solution": "The solution requires implementing a Linear Discriminant Analysis (LDA) classifier pipeline as specified.\n\n### 1. Feature Extraction\nFirst, we define a function to extract the two features for any given sample:\n-   **Feature 1 ($\\cos(\\theta)$):** Cosine similarity of the sample's SNV spectrum to the reference SBS6 signature.\n-   **Feature 2 ($r$):** The fraction of indels in a microsatellite context.\nThis function must handle cases where a feature is absent (due to zero total SNVs or indels) by returning `None`.\n\n### 2. Model Training\nNext, we process the training data to build the classifier.\n-   Extract the feature vectors $X = (\\cos(\\theta), r)$ for all 6 training samples.\n-   Separate the feature vectors into two groups based on their IHC label: mismatch repair deficient (MMRd, class +) and proficient (MMRp, class -).\n-   Calculate the mean vector for each class, $\\mu_+$ and $\\mu_-$.\n-   Calculate the sample covariance matrix for each class.\n-   Compute the pooled covariance matrix, $\\Sigma$, using the formula for equal class covariances: $\\Sigma = \\frac{(N_+-1)C_+ + (N_--1)C_-}{N_+ + N_- - 2}$. Since $N_+=N_-=3$, this simplifies to $\\Sigma = (C_+ + C_-)/2$.\n-   Calculate the inverse of the pooled covariance matrix, $\\Sigma^{-1}$.\n\nThe calculated parameters are approximately:\n-   $\\mu_+ = (0.9922, 0.7100)^\\top$\n-   $\\mu_- = (0.7601, 0.2013)^\\top$\n-   $\\Sigma^{-1} = \\begin{pmatrix} 1338.25 & -812.98 \\\\ -812.98 & 1022.95 \\end{pmatrix}$\n\n### 3. Classifier Construction\nThe decision rule for a sample with feature vector $X$ is to classify as MMRd if $g_+(X) \\ge g_-(X)$. With equal priors, this simplifies to a linear classifier of the form $w^\\top X + b \\ge 0$.\n-   $w = \\Sigma^{-1}(\\mu_+ - \\mu_-) \\approx (71.18, 412.01)^\\top$\n-   $b = -\\frac{1}{2}(\\mu_+^\\top \\Sigma^{-1} \\mu_+ - \\mu_-^\\top \\Sigma^{-1} \\mu_-) \\approx -203.20$\nThe decision rule is: classify as MMRd if $71.18 \\cos(\\theta) + 412.01 r - 203.20 \\ge 0$.\n\nFor cases with missing features (marginalization), we need 1D thresholds. For a 1D LDA with equal priors and variance, the threshold is the midpoint of the means.\n-   If only $r$ is present, classify as MMRd if $r \\ge (\\mu_{+,r} + \\mu_{-,r}) / 2 \\approx 0.4557$.\n-   If only $\\cos(\\theta)$ is present, classify as MMRd if $\\cos(\\theta) \\ge (\\mu_{+,\\cos\\theta} + \\mu_{-,\\cos\\theta}) / 2 \\approx 0.8762$.\n\n### 4. Prediction on Test Set\nWe apply the classifier to the 8 test samples:\n1.  **Test 1**: $X=(0.9982, 0.7222)$. Decision value = $165.48 \\ge 0$. Prediction: **MMRd (True)**.\n2.  **Test 2**: $X=(0.7854, 0.1786)$. Decision value = $-73.68 < 0$. Prediction: **MMRp (False)**.\n3.  **Test 3**: SNV feature absent. $r=0.8 \\ge 0.4557$. Prediction: **MMRd (True)**.\n4.  **Test 4**: Indel feature absent. $\\cos\\theta=0.6566 < 0.8762$. Prediction: **MMRp (False)**.\n5.  **Test 5**: $X=(0.7499, 0.7)$. Decision value = $138.58 \\ge 0$. Prediction: **MMRd (True)**.\n6.  **Test 6**: $X=(0.9944, 0.1)$. Decision value = $-91.22 < 0$. Prediction: **MMRp (False)**.\n7.  **Test 7**: $X=(0.7429, 0.1818)$. Decision value = $-75.46 < 0$. Prediction: **MMRp (False)**.\n8.  **Test 8**: $X=(0.9684, 1.0)$. Decision value = $277.67 \\ge 0$. Prediction: **MMRd (True)**.\n\nThe list of predictions is `[True, False, True, False, True, False, False, True]`.\n\n### 5. Performance Validation\nWe compare the predictions to the true IHC labels `[1, 0, 1, 0, 1, 0, 0, 1]` (True=1, False=0).\n-   True Positives (TP): 4 (Samples 1, 3, 5, 8)\n-   True Negatives (TN): 4 (Samples 2, 4, 6, 7)\n-   False Positives (FP): 0\n-   False Negatives (FN): 0\n\nThe classifier achieves perfect separation on this test set. We calculate the metrics:\n-   **Sensitivity** (TPR) = $TP / (TP+FN) = 4 / (4+0) = 1.0$.\n-   **Specificity** (TNR) = $TN / (TN+FP) = 4 / (4+0) = 1.0$.\n-   **Precision** = $TP / (TP+FP) = 4 / (4+0) = 1.0$.\n-   **F1 Score** = $2 \\cdot (Precision \\cdot Sensitivity) / (Precision + Sensitivity) = 2 \\cdot (1.0 \\cdot 1.0) / (1.0 + 1.0) = 1.0$.\n-   **Balanced Accuracy** = $(Sensitivity + Specificity) / 2 = (1.0 + 1.0) / 2 = 1.0$.\n\nRounding to three decimal places, the metrics are `[1.000, 1.000, 1.000, 1.000]`.", "answer": "[[True,False,True,False,True,False,False,True],[1.000,1.000,1.000,1.000]]", "id": "5025740"}]}